nach oben

Erschienen in:

16.04.2024 | REVIEW

Ablation of Kidney Tumors in Patients with Substantial Kidney Impairment: Current Status

verfasst von: Toshihiro Iguchi, Yusuke Matsui, Koji Tomita, Mayu Uka, Noriyuki Umakoshi, Takahiro Kawabata, Hideo Gobara, Motoo Araki, Takao Hiraki

Erschienen in: Current Oncology Reports | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

To review the current status of kidney tumor ablation in patients with substantial kidney impairment.

Recent findings

Few reports of kidney tumor ablation in such patients have recently been published. The reported prevalence of patients with stage 4 or 5 chronic kidney disease (CKD) among patients undergoing ablation is 2.0%–10%. In patients with stage 4 or 5 CKD, local tumor control rates were 88%–100%. The effect of ablation on CKD stage is unclear, and the observed deteriorations in kidney function are consistent with both the effect of cryoablation and the natural course of advanced CKD.

Summary

According to guidelines, active surveillance may be selected. The goals of treatment are complete tumor removal and maintenance of kidney function, both of which can be met by ablation. Given the limited treatment options, ablation may play a pivotal role in the management of patients with advanced CKD.

Finelli A, Ismaila N, Bro B, Durack J, Eggener S, Evans A, et al. Management of small renal masses: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2017;35:668–80. https://doi.org/10.1200/JCO.2016.69.9645.CrossRefPubMed

Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, et al. European association of urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol. 2022;82:399–410. https://doi.org/10.1016/j.eururo.2022.03.006.CrossRefPubMed

Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:706–20. https://doi.org/10.1093/annonc/mdz056.CrossRefPubMed

Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, et al. Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:71–90. https://doi.org/10.6004/jnccn.2022.0001.CrossRefPubMedPubMedCentral

Campbell SC, Clark PE, Chang SS, Karam JA, Souter L, Uzzo RG. Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part I. J Urol. 2021;206:199–208. https://doi.org/10.1097/JU.0000000000001911.CrossRefPubMed

Park BK, Shen SH, Fujimori M, Wang Y. Asian conference on tumor ablation guidelines for renal cell carcinoma. Investig Clin Urol. 2021;62:378–88. https://doi.org/10.4111/icu.20210168.CrossRefPubMedPubMedCentral

Bertolotti L, Bazzocchi MV, Iemma E, Pagnini F, Ziglioli F, Maestroni U, et al. Radiofrequency ablation, cryoablation, and microwave ablation for the treatment of small renal masses: efficacy and complications. Diagnostics (Basel). 2023;13:388. https://doi.org/10.3390/diagnostics13030388.CrossRefPubMed

Mukkamala A, He C, Weizer AZ, Hafez KS, Miller DC, Montgomery JS, et al. Long-term renal functional outcomes of minimally invasive partial nephrectomy for renal cell carcinoma. Urol Oncol. 2014;32:1247–51. https://doi.org/10.1016/j.urolonc.2014.04.012.CrossRefPubMed

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305. https://doi.org/10.1056/NEJMoa041031.CrossRefPubMed

10.

Park IC, Yoon SK, Kim DW. Risk factors for renal function Impairment following radiofrequency ablation of renal tumors. Taehan Yongsang Uihakhoe Chi. 2022;83:317–30. https://doi.org/10.3348/jksr.2021.0076.CrossRefPubMed

11.

Patel HD, Pierorazio PM, Johnson MH, Sharma R, Iyoha E, Allaf ME, et al. Renal functional outcomes after surgery, ablation, and active surveillance of localized renal tumors: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2017;12:1057–69. https://doi.org/10.2215/CJN.11941116.CrossRefPubMedPubMedCentral

12.

Campbell SC, Clark PE, Chang SS, Karam JA, Souter L, Uzzo RG. Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part II. J Urol. 2021;206:209–18. https://doi.org/10.1097/JU.0000000000001912.CrossRefPubMed

13.

• Umakoshi N, Iguchi T, Matsui Y, Tomita K, Uka M, Kawabata T, et al. Renal cryoablation combined with prior transcatheter arterial embolization in non-dialysis patients with stage 4 or 5 chronic kidney disease: a retrospective study. Jpn J Radiol. 2023;41:1007–14. https://doi.org/10.1007/s11604-023-01416-z. This article showed cryoablation combined with prior TAE for RCC in non-dialysis patients with stage 4 or 5 CKD was effective and safe with an acceptable impact on renal function.CrossRefPubMedPubMedCentral

14.

Lin Y, Liang P, Yu XL, Yu J, Cheng ZG, Han ZY, Liu F. Percutaneous microwave ablation of renal cell carcinoma is safe in patients with renal dysfunction. Int J Hyperthermia. 2017;33:440–5. https://doi.org/10.1080/02656736.2016.1266699.CrossRefPubMed

15.

Woldu SL, Thoreson GR, Okhunov Z, Ghandour R, Rothberg MB, RoyChoudhury A, et al. Comparison of renal parenchymal volume preservation between partial nephrectomy, cryoablation, and radiofrequency ablation using 3D volume measurements. J Endourol. 2015;29:948–55. https://doi.org/10.1089/end.2014.0866.CrossRefPubMed

16.

Gunn AJ, Parikh NS, Bhatia S. Society of interventional radiology quality improvement standards on percutaneous ablation in renal cell carcinoma. J Vasc Interv Radiol. 2020;31:195–201.e3. https://doi.org/10.1016/j.jvir.2019.11.004.CrossRefPubMed

17.

Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. Radiographics. 2005;25:S69–83. https://doi.org/10.1148/rg.25si055501.CrossRefPubMed

18.

Xiaobing W, Wentao G, Guangxiang L, Fan Z, Weidong G, Hongqian G, Gutian Z. Comparison of radiofrequency ablation and partial nephrectomy for tumor in a solitary kidney. BMC Urol. 2017;17:79. https://doi.org/10.1186/s12894-017-0269-4.CrossRefPubMedPubMedCentral

19.

Raman JD, Jafri SM, Qi D. Kidney function outcomes following thermal ablation of small renal masses. World J Nephrol. 2016;5:283–7. https://doi.org/10.5527/wjn.v5.i3.283.CrossRefPubMedPubMedCentral

20.

Ryoo H, Kang M, Sung HH, Jeon HG, Jeong BC, Jeon SS, et al. A comparison of functional and oncologic outcomes between partial nephrectomy and radiofrequency ablation in patients with chronic kidney disease after propensity score matching. Diagnostics (Basel). 2022;12:2292. https://doi.org/10.3390/diagnostics12102292.CrossRefPubMed

21.

Lai WJ, Chung HJ, Chen CK, Shen SH, Chou HP, Chiou YY, et al. Percutaneous computed tomography-guided cryoablation for renal tumor: experience in 30 cases. J Chin Med Assoc. 2015;78:308–15. https://doi.org/10.1016/j.jcma.2014.12.006.CrossRefPubMed

22.

Mason RJ, Atwell TD, Lohse C, Bhindi B, Weisbrod A, Boorjian SA, et al. Renal functional outcomes in patients undergoing percutaneous cryoablation or partial nephrectomy for a solitary renal mass. BJU Int. 2017;120:544–9. https://doi.org/10.1111/bju.13917.CrossRefPubMed

23.

Gobara H, Nakatsuka A, Shimizu K, Yamanaka T, Matsui Y, Iguchi T, et al. Cryoablation of renal cell carcinoma for patients with stage 4 or 5 non-dialysis chronic kidney disease. Jpn J Radiol. 2019;37:481–6. https://doi.org/10.1007/s11604-019-00821-7.CrossRefPubMed

24.

Asayama Y, Nishie A, Ushijima Y, Okamoto D, Morita K, Takao S, et al. Usefulness of a pretreatment CT-based modified RENAL nephrometry score in predicting renal function after cryotherapy for T1a renal mass. Cardiovasc Intervent Radiol. 2019;42:1128–34. https://doi.org/10.1007/s00270-019-02238-1.CrossRefPubMed

25.

John JB, Anderson M, Dutton T, Stott M, Crundwell M, Llewelyn R, et al. Percutaneous microwave ablation of renal masses in a UK cohort. BJU Int. 2021;127:486–94. https://doi.org/10.1111/bju.15224.CrossRefPubMed

26.

Knudsen JS, Duus LA, Mussmann B, Graumann O. Percutaneous renal tumor cryoablation effect on renal function. J Endourol. 2023;37:1149–55. https://doi.org/10.1089/end.2021.0959.CrossRefPubMed

27.

Lum MA, Shah SB, Durack FC, Nikolovski I. Imaging of small renal masses before and after thermal ablation. Radiographics. 2019;39:2134–45. https://doi.org/10.1148/rg.2019190083.CrossRefPubMed

28.

Umakoshi N, Iguchi T, Hiraki T, Matsui Y, Tomita K, Uka M, et al. Correlation between renal ablation zone in contrast-enhanced CT and non-enhanced MRI during the early period following percutaneous cryoablation. Jpn J Radiol. 2022;40:1087–95. https://doi.org/10.1007/s11604-022-01285-y.CrossRefPubMedPubMedCentral

29.

Guo F, Hu B, Chen L, Li J. Clinical application of contrast-enhanced ultrasound after percutaneous renal tumor ablation. Br J Radiol. 2019;92:20190183. https://doi.org/10.1259/bjr.20190183.CrossRefPubMedPubMedCentral

30.

Zeccolini G, Del Biondo D, Cicero C, Casarin A, Guarise A, Celia A. Comparison of Contrast-Enhanced Ultrasound Scan (CEUS) and MRI in the follow-up of cryoablation for small renal tumors. Experience on 25 cases. Urologia. 2014;81 Suppl 23:S1–8. https://doi.org/10.5301/RU.2014.11986.CrossRefPubMed

31.

Tsivian M, Rampersaud EN Jr, del Pilar Laguna Pes M, Joniau S, Leveillee RJ, Shingleton WB, et al. Small renal mass biopsy-how, what and when: report from an international consensus panel. BJU Int. 2014;113:854–63. https://doi.org/10.1111/bju.12470.CrossRefPubMed

32.

Domi R, Huti G, Sula H, Baftiu N, Kaci M, Bodeci A, Pesha A. From pre-existing renal failure to perioperative renal protection: the anesthesiologist’s dilemmas. Anesth Pain Med. 2016;6:e32386. https://doi.org/10.5812/aapm.32386.CrossRefPubMedPubMedCentral

33.

Truesdale CM, Soulen MC, Clark TW, Mondschein JI, Wehrenberg-Klee E, Malkowicz SB, et al. Percutaneous computed tomography-guided renal mass radiofrequency ablation versus cryoablation: doses of sedation medication used. J Vasc Interv Radiol. 2013;24:347–50. https://doi.org/10.1016/j.jvir.2012.11.022.CrossRefPubMed

34.

De Marini P, Cazzato RL, Garnon J, Dalili D, Leonard-Lorant I, Leclerc L, et al. Safety and oncologic efficacy of percutaneous MRI-guided cryoablation of intraparenchymal renal cancers. Diagn Interv Imaging. 2021;102:531–8. https://doi.org/10.1016/j.diii.2021.04.002.CrossRefPubMed

35.

Cazzato RL, De Marini P, Mayer T, Leclerc L, Leonard-Lorant I, Dalili D, et al. MRI- versus CT-guided renal tumor cryoablation: is there a difference? Cardiovasc Intervent Radiol. 2023;46:901–10. https://doi.org/10.1007/s00270-023-03453-7.CrossRefPubMed

36.

Michimoto K, Shimizu K, Kameoka Y, Sadaoka S, Miki J, Kishimoto K. Transcatheter arterial embolization with a mixture of absolute ethanol and iodized oil for poorly visualized endophytic renal masses prior to CT-guided percutaneous cryoablation. Cardiovasc Intervent Radiol. 2016;39:1589–94. https://doi.org/10.1007/s00270-016-1414-2.CrossRefPubMed

37.

Hisano M, Katsumori T, Yoshikawa T, Yasumura T, Sasakura Y. Percutaneous direct lipiodol marking for CT-guided cryoablation for small renal tumors. J Vasc Interv Radiol. 2021;32:630–3. https://doi.org/10.1016/j.jvir.2020.12.004.CrossRefPubMed

38.

Pietryga JA, Beland MD, Dupuy DE, Maya-Smith WW. Placement of marker coils at biopsy: usefulness in the localization of poorly visualized renal neoplasms for subsequent CT-guided radiofrequency ablation. Radiology. 2012;263:555–61. https://doi.org/10.1148/radiol.12111430.CrossRefPubMed

39.

Yu J, Liang P, Yu XL, Cheng ZG, Han ZY, Zhang X, et al. US-guided percutaneous microwave ablation versus open radical nephrectomy for small renal cell carcinoma: intermediate-term results. Radiology. 2014;270:880–7. https://doi.org/10.1148/radiol.13130275.CrossRefPubMed

40.

Nguyen CT, Lane BR, Kaouk JH, Hegarty N, Gill IS, Novick AC, Campbell SC. Surgical salvage of renal cell carcinoma recurrence after thermal ablative therapy. J Urol. 2008;180:104–9. https://doi.org/10.1016/j.juro.2008.03.046.CrossRefPubMed

41.

El Dib R, Touma NJ, Kapoor A. Cryoablation vs radiofrequency ablation for the treatment of renal cell carcinoma: a meta-analysis of case series studies. BJU Int. 2012;110:510–6. https://doi.org/10.1111/j.1464-410X.2011.10885.x.CrossRefPubMed

42.

Iguchi T, Matsui Y, Tomita K, Uka M, Umakoshi N, Kawabata T, et al. Complications of percutaneous cryoablation for renal tumors and methods for avoiding them. Acta Med Okayama. 2023;77:121–9. https://doi.org/10.18926/AMO/65141.CrossRefPubMed

43.

Kakarala B, Frangakis CE, Rodriguez R, Georgiades CS. Hemorrhagic complications of percutaneous cryoablation for renal tumors: results from a 7-year prospective study. Cardiovasc Intervent Radiol. 2016;39:1604–10. https://doi.org/10.1007/s00270-016-1419-x.CrossRefPubMed

44.

Atwell TD, Carter RE, Schmit GD, Carr CM, Boorjian SA, Curry TB, et al. Complications following 573 percutaneous renal radiofrequency and cryoablation procedures. J Vasc Interv Radiol. 2012;23:48–54. https://doi.org/10.1016/j.jvir.2011.09.008.CrossRefPubMed

45.

Moynagh MR, Schmit GD, Thompson RH, Boorjian SA, Woodrum DA, Curry TB, Atwell TD. Percutaneous cryoablation of clinical T2 (>7 cm) renal masses: technical considerations, complications, and short-term outcomes. J Vasc Interv Radiol. 2015;26:800–6. https://doi.org/10.1016/j.jvir.2015.02.013.CrossRefPubMed

46.

McElroy KM, Reisenauer CJ, Welch BT, Takahashi EA, Frimpong RG, Atwell TD, et al. Long-term renal function outcomes after renal cryoablation complicated by major hemorrhage requiring selective transarterial embolization. Abdom Radiol (NY). 2021;46:4898–907. https://doi.org/10.1007/s00261-021-03182-w.CrossRefPubMed

47.

Yamagami T, Yoshimatsu R, Kajiwara K, Yamanishi T, Minamiguchi H, Karashima T, Inoue K. Protection from injury of organs adjacent to a renal tumor during percutaneous cryoablation. Int J Urol. 2019;26:785–90. https://doi.org/10.1111/iju.14013.CrossRefPubMed

48.

Zhao Y, Matsui Y, Hiraki T, Iguchi T, Masaoka Y, Kanazawa S. Six cases of radiographic ice ball involvement of the ureter during percutaneous cryoablation for renal cancers. Cardiovasc Intervent Radiol. 2020;43:344–6. https://doi.org/10.1007/s00270-019-02358-8.CrossRefPubMed

49.

Rosenberg MD, Kim CY, Tsivian M, Suberlak MN, Sopko DR, Polascik TJ, Nelson RC. Percutaneous cryoablation of renal lesions with radiographic ice ball involvement of the renal sinus: analysis of hemorrhagic and collecting system complications. AJR Am J Roentgenol. 2011;196:935–9. https://doi.org/10.2214/AJR.10.5182.CrossRefPubMed

50.

Zhou W, Herwald SE, McCarthy C, Uppot RN, Arellano RS. Radiofrequency ablation, cryoablation and microwave ablation for T1a renal cell carcinoma: a comparative evaluation of therapeutic and renal function outcomes. J Vasc Interv Radiol. 2019;30:1035–42. https://doi.org/10.1016/j.jvir.2018.12.013.CrossRefPubMed

51.

Rivero JR, De La Cerda J 3rd, Wang H, Liss MA, Farrell AM, Rodriguez R, et al. Partial nephrectomy versus thermal ablation for clinical stage T1 renal masses: systematic review and metaanalysis of more than 3,900 patients. J Vasc Interv Radiol. 2018;29:18–29. https://doi.org/10.1016/j.jvir.2017.08.013.CrossRefPubMed

52.

Zhou W, Herwald SE, Uppot RN, Arellano RS. Risk Assessment of chronic kidney disease following microwave ablation for stage T1 renal cell carcinoma. J Vasc Interv Radiol. 2018;29:1685–91. https://doi.org/10.1016/j.jvir.2018.06.021.CrossRefPubMed

53.

Wehrenberg-Klee E, Clark TWI, Malkowicz SB, Soulen MC, Wein AJ, Mondschein JI, et al. Impact on renal function of percutaneous thermal ablation of renal masses in patients with preexisting chronic kidney disease. J Vasc Interv Radiol. 2012;23:41–5. https://doi.org/10.1016/j.jvir.2011.09.002.CrossRefPubMed

54.

Bhindi B, Thompson RH, Mason RJ, Haddad MM, Geske JR, Kurup AN, et al. Comprehensive assessment of renal tumour complexity in a large percutaneous cryoablation cohort. BJU Int. 2017;119:905–12. https://doi.org/10.1111/bju.13841.CrossRefPubMed

55.

Zhou W, Uppot RN, Feldman AS, Arellano RS. Percutaneous image-guided thermal ablation for multifocal renal cell carcinoma: 10-year experience at a single center. AJR Am J Roentgenol. 2017;209:733–9. https://doi.org/10.2214/AJR.17.18290.CrossRefPubMed

56.

Larcher A, Meskawi M, Valdivieso R, Boehm K, Trudeau V, Tian Z, Fossati N, et al. Comparison of renal function detriments after local tumor ablation or partial nephrectomy for renal cell carcinoma. World J Urol. 2016;34:383–9. https://doi.org/10.1007/s00345-015-1606-4.CrossRefPubMed

57.

Park SY, Park BK, Kim CK. Thermal ablation in renal cell carcinoma: what affects renal function? Int J Hyperthermia. 2012;28:729–34. https://doi.org/10.3109/02656736.2012.728017.CrossRefPubMed

58.

Park BK, Gong IH, Kang MY, Sung HH, Jeon HG, Jeong BC, et al. RFA versus robotic partial nephrectomy for T1a renal cell carcinoma: A propensity score-matched comparison of mid-term outcome. Eur Radiol. 2018;28:2979–85. https://doi.org/10.1007/s00330-018-5305-6.CrossRefPubMed

59.

Takagi T, Kondo T, Omae K, Iizuka J, Kobayashi H, Yoshida K, et al. Comparison of progression to end-stage renal disease requiring dialysis after partial or radical nephrectomy for renal cell carcinoma in patients with severe chronic kidney disease. Int Urol Nephrol. 2016;48:1421–7. https://doi.org/10.1007/s11255-016-1317-9.CrossRefPubMed

Titel: Ablation of Kidney Tumors in Patients with Substantial Kidney Impairment: Current Status
verfasst von: Toshihiro Iguchi
Yusuke Matsui
Koji Tomita
Mayu Uka
Noriyuki Umakoshi
Takahiro Kawabata
Hideo Gobara
Motoo Araki
Takao Hiraki
Publikationsdatum: 16.04.2024
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 5/2024
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-024-01533-6

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Ablation of Kidney Tumors in Patients with Substantial Kidney Impairment: Current Status